Skip to content

Search

The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial

Structural lung disease and neutrophil-dominated airway inflammation is present from 3 months of age in children diagnosed with cystic fibrosis after newborn screening. We hypothesised that azithromycin, given three times weekly to infants with cystic fibrosis from diagnosis until age 36 months, would reduce the extent of structural lung disease as captured on chest CT scans.

Tracking the impact of early treatment in young children with cystic fibrosis

For decades, cystic fibrosis (CF) meant a life shaped by daily treatments, frequent hospitalisations, and an uncertain future. The arrival of CFTR modulators has changed that picture dramatically, and researchers at the Wal-yan Respiratory Research Centre now want to understand the bigger picture.

Rising carbon dioxide levels detected in human blood, new study finds

Rising carbon dioxide levels are being detected within the human body, with new research warning a key blood marker for the gas could near its healthy limit within decades if current trends continue.

Reducing the asthma burden: generous grant secured to develop world-first treatment

Researchers developing a world-first treatment that targets an underlying cause of asthma have secured a $499,640 grant from the Future Health, Research and Innovation Fund – Innovation Seed Fund.

Aspire Award funds global learning opportunity

Dr Renee Ng, a microbiologist specialising in bacteriophage therapy – an alternative to antibiotics to fight antimicrobial resistance – will travel to the world’s premier conference on viruses, bringing new ideas, connections and expertise back to Perth.

Major grant supports innovative infant lung health study

A ground-breaking global clinical trial to improve the lifelong lung health of children born extremely prematurely has been awarded a Medical Research Future Fund (MRFF) International Clinical Trials Collaborations Grant totalling almost $3 million.

Community partnership sets priorities for preterm lung health research

Respiratory disease remains one of the most significant complications of preterm birth, with lasting consequences.

New funding to accelerate AI personalised phage therapies

Wal-yan researchers have been awarded $500,000 for their innovative research, supported by the Western Australian Government’s Future Health Medical Research and Innovation (FHRI) Fund.

National funding for bright ideas targeting ear infections and dangerous fungi

Two projects led by The Kids Research Institute Australia have been awarded more than $2.5 million to fund innovative ideas focused, respectively, on combating persistent ear infections and investigating how dangerous fungi invade the bodies of immunocompromised people.